Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Response Time For DTC Ad Advisory Comments Has Doubled, Agency Says

Executive Summary

FDA has increased from two to four weeks the time it takes to return direct-to-consumer broadcast ads with advisory comments due to the enlarged volume of submissions, Division of Drug Marketing, Advertising & Communications Branch Chief Nancy Ostrove, PhD, reported Sept. 13 at a Food & Drug Law Institute conference on "Marketing and Promotion in the New Millennium."

You may also be interested in...



FDA Phone Call Preceded Untitled Letter To Lilly Over Amyvid

Lilly promised to remove offending images from promotional materials for its imaging product, but the agency followed up with a “notice of violation” letter two months later anyway.

FDA Reminder Ad Scrutiny: Viagra Valentine, Flonase Flora Cited

FDA's ad division is looking for drug "reminder" ads that go too far in terms of implied product claims, Division of Drug Marketing, Advertising & Communications Branch Chief Nancy Ostrove, PhD, indicated at a Drug Information Association meeting in New York City Feb. 28.

FDA Reminder Ad Scrutiny: Viagra Valentine, Flonase Flora Cited

FDA's ad division is looking for drug "reminder" ads that go too far in terms of implied product claims, Division of Drug Marketing, Advertising & Communications Branch Chief Nancy Ostrove, PhD, indicated at a Drug Information Association meeting in New York City Feb. 28.

Related Content

UsernamePublicRestriction

Register

PS034845

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel